Enhanced tryptophan degradation in patients with ovarian carcinoma correlates with several serum soluble immune activation markers

Immunobiology

Volumn 216, Issue 3, 2011, Pages 296-301

  Sperner Unterweger, Barbara ^a   Neurauter, Gabriele ^a   Klieber, Martin ^a   Kurz, Katharina ^b   Meraner, Verena ^a   Zeimet, Alain ^a   Fuchs, Dietmar ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

IL 6; Immune activation; Indoleamine 2,3 dioxygenase (IDO); Kynurenine; Kynurenine to tryptophan ratio (kyn trp); Neopterin; Soluble cytokine receptors; TNF ; Tryptophan

Indexed keywords

INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; KYNURENINE; NEOPTERIN; TRYPTOPHAN; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CANCER GRADING; CONTROLLED STUDY; CORRELATIONAL STUDY; DEGRADATION KINETICS; ENZYME ACTIVITY; FEMALE; HUMAN; IMMUNOSTIMULATION; MACROPHAGE ACTIVATION; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRYPTOPHAN METABOLISM; TUMOR ESCAPE;

ADULT; AGED; FEMALE; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; INTERLEUKIN-6; KYNURENINE; MIDDLE AGED; NEOPTERIN; OVARIAN NEOPLASMS; RECEPTORS, TUMOR NECROSIS FACTOR; TRYPTOPHAN;

EID: 79251595590     PISSN: 01712985     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imbio.2010.07.010     Document Type: Article

References (51)

1. Aderka D., Engelmann H., Hornik V. Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients. Cancer Res. 1991, 51:5602-5607.
2. Brandacher G., Perathoner A., Ladurner R., Schneeberger S., Obrist P., Winkler C., Werner E.R., Werner-Felmayer G., Weiss H.G., Goebel G., Margreiter R., Koenigsrainer A., Fuchs D., Amberger A. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: impact on tumor-infiltrating T-cells. Clin. Cancer Res. 2006, 12:1144-1151.
3. Brandacher G., Winkler C., Schroecksnadel K., Margreiter R., Fuchs D. Antitumoral activity of interferon-γ involved in impaired immune function in cancer patients. Curr. Drug Metabol. 2006, 7:599-612.
4. Brown R.R., Ozaki Y., Datta S.P., Borden E.C., Sondel P.M., Malone D.G. Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS. Adv. Exp. Med. Biol. 1991, 294:425-435.
5. Carlin J.M., Ozaki Y., Byrne G.I., Brown R.R., Borden E.C. Interferons and indoleamine 2,3-dioxygenase: role in antimicrobial and antitumor effects. Experientia 1989, 45:535-541.
6. Cordingley F.T., Bianchi A., Hoffbrand A.V., Reittie J.E., Heslop H.E., Vyakarnam A., Turner M., Meager A., Brenner M.K. Tumor necrosis factor as an autocrine tumor growth factor for chronic B cell malignancies. Lancet 1988, 1:969-971.
7. Denz H., Orth B., Weiss G., Herrmann R., Huber P., Wachter H., Fuchs D. Weight loss in patients with hematological neoplasias is associated with immune system stimulation. Clin. Invest. 1993, 71:37-41.
8. Denz H., Orth B., Weiß G., Gallati H., Herrmann R., Huber P., Wachter H., Fuchs D. Serum soluble tumour necrosis factor receptor 55 is increased in patients with haematological neoplasias and is associated with immune activation and weight loss. Eur. J. Cancer 1993, 29A:2232-2235.
9. Diez-Ruiz A., Tilz G.P., Zangerle R., Baier-Bitterlich G., Wachter H., Fuchs D. Soluble receptors for tumor necrosis factor in clinical laboratory diagnosis. Eur. J. Haematol. 1995, 54:1-8.
10. Fallarino F., Grohmann U., Vacca C., Bianchi R., Orabona C., Spreca A., Fioretti M.C., Puccetti P. T cell apoptosis by tryptophan catabolism. Cell Death Differ. 2002, 9:1069-1077.
11. Giusti R.M., Maloney E.M., Hanchard B., Morgan O.S., Steinberg S.M., Wachter H., Williams E., Cranston B., Fuchs D., Manns A. Differential patterns of serum biomarkers of immune activation in human T-cell lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis, and adult T-cell leukemia/lymphoma. Cancer Epidemiol. Biomarkers Prev. 1996, 5:699-704.
12. Hasday J.D., Shah E.M., Lieberman A.P. Macrophage tumor necrosis factor-alpha release is induced by contact with some tumors. J. Immunol. 1990, 145:371-379.
13. Hirano T., Akira S., Taga T., Kishimoto T. Biological and clinical aspects of interleukin 6. Immunol. Today 1990, 11:443-449.
14. Huang A., Fuchs D., Widner B., Glover C., Henderson D.C., Allen-Mersh T.G. Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer. Br. J. Cancer 2002, 86:1691-1696.
15. Huber C., Batchelor J.R., Fuchs D., Hausen A., Lang A., Niederwieser D., Reibnegger G., Swetly P., Troppmair J., Wachter H. Immune response-associated production of neopterin-release from macrophages primarily under control of interferon-gamma. J. Exp. Med. 1984, 160:310-316.
16. Inaba T., Ino K., Kajiyama H., Yamamoto E., Shibata K., Nawa A., Nagasaka T., Akimoto H., Takikawa O., Kikkawa F. Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma. Gynecol. Oncol. 2009, 115:185-192.
17. Irschick E.U., Sgonc R., Böck G., Wolf H., Fuchs D., Nussbaumer W., Göttinger W., Huemer H.P. Retinal pigment epithelial phagocytosis and metabolism differ from those of macrophages. Ophthalmic Res. 2006, 36:195-205.
18. Iwagaki H., Hizuta A., Tanaka N., Orita K. Decreased serum tryptophan in patients with cancer cachexia correlates with increased serum neopterin. Immunol. Invest. 1995, 24:467-478.
19. Kronberger P., Weiss G., Tschmelitsch J., Fuchs D., Salzer G.M., Wachter H., Reibnegger G. Predictive value of urinary neopterin in patients with lung cancer. Eur. J. Clin. Chem. Clin. Biochem. 1995, 33:831-837.
20. Kurzrock R., Redman J., Cabanillas F., Jones D., Rothberg J., Talpaz M. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms. Cancer Res. 1993, 53:2118-2122.
21. Langkopf F., Atzpodien J. Soluble tumor necrosis factor receptors as prognostic factors in cancer patients. Lancet 1994, 344:57-58.
22. Lewenhaupt A., Ekman P., Eneroth P., Eriksson A., Nilsson B., Nordstrom L. Serum levels of neopterin as related to the prognosis of human prostatic carcinoma. Eur. Urol. 1986, 12:422-425.
23. Loeb S., Koenigsrainer A. Is IDO a key enzyme bridging the gap between tumor escape and tolerance induction?. Langenbecks Arch. Surg. 2008, 393:995-1003.
24. Marth C., Windbichler G.H., Hausmaninger H., Petru E., Estermann K., Pelzer A., Mueller-Holzner E. Interferon-gamma in combination with carboplatin and paclitaxel as a safe and effective first-line treatment option for advanced ovarian cancer: results of a phase I/II study. Int. J. Gynecol. Cancer 2006, 16:1522-1528.
25. Mellor A.L., Munn D.H. Tryptophan catabolism and regulation of adaptive immunity. J. Immunol. 2003, 170:5809-5812.
26. Munn D.H., Zhou M., Attwood J.T., Bondarev I., Conway S.J., Marshall B., Brown C., Mellor A.L. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998, 281:1191-1193.
27. Munn D.H., Sharma M.D., Hou D., Baban B., Lee J.R., Antonia S.J., Messina J.L., Chandler P., Koni P.A., Mellor A.L. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J. Clin. Invest. 2004, 114:280-290.
28. Murr C., Bergant A., Widschwendter M., Heim K., Schrocksnadel H., Fuchs D. Neopterin is an independent prognostic variable in females with breast cancer. Clin. Chem. 1999, 45:1998-2004.
29. Pfefferkorn E.R., Eckel M., Rebhun S. Interferon-gamma suppresses the growth of Toxoplasma gondii in human fibroblasts through starvation for tryptophan. Mol. Biochem. Parasitol. 1986, 20:215-224.
30. Pizzolo G., Chilosi M., Semenzato G. The soluble interleukin-2 receptor in haematological disorders. Br. J. Haematol. 1987, 67:377-380.
31. Reibnegger G.J., Bichler A.H., Dapunt O., Fuchs D.N., Fuith L.C., Hausen A., Hetzel H.M., Lutz H., Werner E.R., Wachter H. Neopterin as a prognostic indicator in patients with carcinoma of the uterine cervix. Cancer Res. 1986, 46:950-955.
32. Reibnegger G., Hetzel H., Fuchs D., Fuith L.C., Hausen A., Werner E.R., Wachter H. Clinical significance of neopterin for prognosis and follow-up in ovarian cancer. Cancer Res. 1987, 47:4977-4981.
33. Reibnegger G., Krainer M., Herold M., Ludwig H., Wachter H., Huber H. Predictive value of interleukin-6 and neopterin in patients with multiple myeloma. Cancer Res. 1991, 51:6250-6253.
34. Schepers K., Schumacher T.N.M. Tumors hijack fetal enzyme, escape killer T cells. Nat. Med. 2003, 9:1253-1254.
35. Schmeler K.M., Vadhan-Raj S., Ramirez P.T., Apte S.M., Cohen L., Bassett R.L., Iyer R.B., Wolf J.K., Levenback C.L., Gershenson D.M., Freedman R.S. A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer. Gynecol. Oncol. 2009, 113:210-215.
36. Schroecksnadel K., Winkler C., Fuith L.C., Fuchs D. Tryptophan degradation in patients with gynecological cancer correlates with immune activation. Cancer Lett. 2005, 223:323-329.
37. Schroecksnadel K., Wirleitner B., Winkler C., Fuchs D. Monitoring tryptophan metabolism in chronic immune activation. Clin. Chim. Acta 2006, 364:82-90.
38. Taylor M.W., Feng G.S. Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J. 1991, 5:2516-2522.
39. Uyttenhove C., Pilotte L., Theate I., Stroobant V., Colau D., Parmentier N., Boon T., Van den Eynde B.J. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 2003, 9:1269-1274.
40. Wagner D.K., Kiwanuka J., Edwards B.K., Rubin L.A., Nelson D.L., Magrath I.T. Soluble interleukin-2 receptor levels in patients with undifferentiated and lymphoblastic lymphomas: correlation with survival. J. Clin. Oncol. 1987, 5:1262-1274.
41. Weinlich G., Murr C., Richardsen L., Winkler C., Fuchs D. Decreased serum tryptophan concentration predicts poor prognosis in malignant melanoma patients. Dermatology 2007, 214:8-14.
42. Weiss G., Kronberger P., Conrad F., Bodner E., Wachter H., Reibnegger G. Neopterin and prognosis in patients with adenocarcinoma of the colon. Cancer Res. 1993, 53:260-265.
43. Werner E.R., Bitterlich G., Fuchs D., Hausen A., Reibnegger G., Szabo G., Dierich M.P., Wachter H. Human macrophages degrade tryptophan upon induction by interferon-gamma. Life Sci. 1987, 41:273-280.
44. Werner E.R., Werner-Felmayer G., Fuchs D., Hausen A., Reibnegger G., Wachter H. Parallel induction of tetrahydrobiopterin biosynthesis and indoleamine 2,3-dioxygenase activity in human cells and cell lines by interferon-gamma. Biochem. J. 1989, 262:861-866.
45. Werner-Felmayer G., Werner E.R., Fuchs D., Hausen A., Reibnegger G., Wachter H. Characteristics of interferon induced tryptophan metabolism in human cells in vitro. Biochim. Biophys. Acta. 1989, 1012:140-147.
46. Widner B., Werner E.R., Schennach H., Wachter H., Fuchs D. Simultaneous measurement of serum tryptophan and kynurenine by HPLC. Clin. Chem. 1997, 43:2424-2426.
47. Wirleitner B., Reider D., Ebner S., Bock G., Widner B., Jaeger M., Schennach H., Romani N., Fuchs D. Monocyte-derived dendritic cells release neopterin. J. Leukoc. Biol. 2002, 72:1148-1153.
48. Wirleitner B., Wirleitner B., Winkler C., Fuchs D. Neopterin in HIV infection. Mol. Immunol. 2005, 42:183-194.
49. Wolf A.M., Wolf D., Rumpold H., Moschen A.R., Kaser A., Obrist P., Fuchs D., Brandacher G., Winkler C., Geboes K., Rutgeerts P., Tilg H. Overexpression of indoleamine 2,3-dioxygenase IDO in human inflammatory bowel disease. Clin. Immunol. 2004, 113:47-55.
50. Wood K.J., Sawitzki B. Interferon gamma: a crucial role in the function of induced regulatory T cells in vivo. Trends Immunol. 2006, 27:183-187.
51. Zangerle R., Widner B., Quirchmair G., Neurauter G., Sarcletti M., Fuchs D. Effective antiretroviral therapy reduces degradation of tryptophan in patients with HIV-1 infection. Clin. Immunol. 2002, 104:242-247.